key: cord-0024985-xc11gv7j
authors: Hebert, Sean A.
title: Renal Consequences of COVID-19
date: 2021-12-15
journal: nan
DOI: 10.14797/mdcvj.1058
sha: 99e1b7992a6b23b1f5a30e44c24c505ad6b287ab
doc_id: 24985
cord_uid: xc11gv7j

The column in this issue is provided by Sean A. Hebert, MD, assistant professor of Clinical Medicine at the Houston Methodist Academic Institute. Dr. Hebert specializes in transplant nephrology at Houston Methodist.

The kidney is one of the major extrapulmonary organs involved in coronavirus disease 2019 (COVID-19) infections, but direct viral access to the kidney is not well understood. Fulminant viremia and viruria are not typical features of COVID-19 patients. Yet, SARS-CoV-2 RNA was detected in kidney tissue in up to 50% of COVID-19 patients on postmortem series. 1 While our understanding of COVID-19 continues to evolve, consider these important aspects of COVID-19 related to kidney disease. 2, 3 • Proteinuria: 65.8%-84% • Hematuria: 41.7%-81% • Acute kidney injury (AKI): 32%-37% • Acute kidney injury (AKI) requiring renal replacement therapy (RRT): 12%-15%

Outcomes 2

• In-hospital mortality is 50% among patients with AKI compared with 8% in those without AKI. • Of all patients with AKI, only 30% survived with recovery of kidney function at hospital discharge.

• There is no evidence that stopping renin angiotensin system inhibitors reduces COVID-19 severity.

Dialysis 5, 6 • Viral transmission is minimal in outpatient in-center dialysis units due to routine disinfection, personal protective equipment, and cohort isolation. • Cumulative incidence is 17% to 20% among in-center dialysis patients. • Increased mortality rate: 25% to 30% compared with the general population of hospitalized COVID-19 patients.

• Increased mortality rate: 13%-30% • Graft loss: 3.4%-6.3%

• Discontinuing the antimetabolite mycophenolate is recommended for patients with severe infection.

Vaccine efficacy [8] [9] [10] [11] • Dialysis: 

The author has no competing interests to declare. 

Evidence For and Against Direct Kidney Infection by SARS-CoV-2 in Patients with COVID-19

AKI in Hospitalized Patients with COVID-19

which permits unrestricted use, distribution, and reproduction in any noncommercial medium, provided the original author and source are credited

Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia

Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial

Epidemiology of COVID-19 in an Urban Dialysis Center

Outcomes of patients with end-stage kidney disease hospitalized with COVID-19

COVID-19 infection in kidney transplant recipients at the epicenter of pandemics

Early Humoral Responses of Hemodialysis Patients after COVID-19 Vaccination with BNT162b2

Kidney Transplant Recipients Rarely Show an Early Antibody Response Following the First COVID-19 Vaccine Administration

Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series